Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

Bet on Wild Swings in the Market With the SPXL ETF

By Dana Blankenhorn, InvestorPlace Contributor

SPXL stock is not for the faint of heart. But if you think the market will keep going up, here's how you can make a big bet with big momentum.

Microchip Technology Stock is an Investment in the Machine Internet

By Dana Blankenhorn, InvestorPlace Contributor

The Machine Internet, which puts sensors, intelligence and connectivity inside common devices, is a big trend of the 2020s and MHCP stock is at the center of it.

Taiwan Semiconductor Is the Most Important Company in the World

By Dana Blankenhorn, InvestorPlace Contributor

Taiwan Semiconductor is mastering semiconductor manufacturing processes that rivals like Intel haven't tried out yet.

7 Hot Cloud Stocks to Buy Now For Long-Term Profits

By Dana Blankenhorn, InvestorPlace Contributor

The five U.S. Cloud Czars are now worth nearly $7 billion, and cloud stocks of all types have been delivering profits in 2020.

Make Sure You Understand the Risks Before Speculating on Ocugen Stock

By Dana Blankenhorn, InvestorPlace Contributor

Ocugen is raising cash through its orphan drug designation, but it still faces risks. Make sure you treat OCGN stock as a speculation.

Load More